<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9736">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02980198</url>
  </required_header>
  <id_info>
    <org_study_id>IFN-K-005-DM</org_study_id>
    <secondary_id>2016-000137-52</secondary_id>
    <nct_id>NCT02980198</nct_id>
  </id_info>
  <brief_title>Study of IFN-K in Dermatomyositis</brief_title>
  <official_title>A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovacs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovacs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Proof of Concept study aiming to evaluate the production of anti-IFNα
      antibodies (immune response) in adult subjects with dermatomyositis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the expression of IFN-induced genes at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment related adverse events</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment with IFN-K as measured by MMT5/MMT8</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment with IFN-K as measured by CDASI</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment with IFN-K as measured by Physician global activity (PGA)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment with IFN-K as measured by Patient Global Activity</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment with IFN-K as measured by Health Assessment Questionnaire (HAQ),Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response induced by IFN-K as measured by antibodies production</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>IFN-Kinoid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN-Kinoid + ISA 51</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + ISA 51</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IFN-Kinoid</intervention_name>
    <arm_group_label>IFN-Kinoid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ISA 51</intervention_name>
    <arm_group_label>IFN-Kinoid</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient newly diagnosed or relapsing with &quot;definite&quot; or &quot;probable&quot; dermatomyositis
             based on ENMC criteria (2004)

          -  Patient with an MMT-8 ≤ 120 and/or an MMT-5 ≤ 22

          -  Patient requiring corticosteroids (CS) at a dose of 1 mg/Kg or ≤ 70 mg of prednisone
             equivalent/day or currently receiving CS at a dose of 1 mg/Kg or ≤ 70 mg of
             prednisone equivalent/day

          -  Is a male or female, aged between 18 and 65 years, inclusive, at the time of the
             screening visit

        Exclusion Criteria:

          -  Is high-risk human papilloma virus (HPV) positive by (RT-qPCR) on a cervical swab

          -  Has cytological abnormalities ≥ HSIL on a cervical swab

          -  Is positive for autoantibodies anti-NXP2, TIF1ɤ, MDA5 or anti-synthetase antibodies

          -  Is positive for any malignancy or has a history of any malignancy

          -  Has received IV pulse dose CS (≥ 250 mg prednisone equivalent/day)

          -  Has received intravenous immunoglobulin (IVIg)

          -  Has received potent immunosuppressive drugs such as cyclophosphamide, methotrexate,
             azathioprine, mycophenolate, cyclosporine A, oral tacrolimus

          -  Has received abatacept, anifrolumab, belimumab, TNF antagonists or another registered
             or investigational biological therapy

          -  Has received anti-B-cell therapy (e.g. rituximab, epratuzumab)

          -  Has received any live vaccine

          -  Has used any investigational or non-registered product , or any investigational or
             non-registered vaccine

          -  Has inflammatory joint or skin disease other than dermatomyositis that may interfere
             with study assessments

          -  Has frequent recurrences of oral or genital herpes simplex lesions

          -  Is at high risk of significant infection and/or has any current signs or symptoms of
             infection at entry or has received intravenous antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Claude Huriez, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Hachulla, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Hachulla, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Schleinitz, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Schleinitz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-David Bouaziz, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-David Bouaziz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière, AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Benveniste, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Benveniste, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg-Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Sibilia, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Sibilia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin Rudolf- Virchow- Haus</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugen Feist, MD, PhD</last_name>
      <email>Eugen.Feist@charite.de</email>
    </contact>
    <investigator>
      <last_name>Eugen Feist, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Doria, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Doria, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hopsitalier Universitaires Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Spertini, MD, PhD</last_name>
      <email>francois.spertini@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>François Spertini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Cooper, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Cooper, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 29, 2016</lastchanged_date>
  <firstreceived_date>November 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
